BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 7189443)

  • 1. Chemotherapy of metastatic bladder cancer.
    Yagoda A
    Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
    Sulkes A; Fuks Z
    Cancer Treat Rep; 1983 Feb; 67(2):200-1. PubMed ID: 6681734
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 4. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
    Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
    [No Abstract]   [Full Text] [Related]  

  • 5. Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract.
    Tannock IF
    Cancer Treat Rep; 1983 May; 67(5):503-4. PubMed ID: 6406061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 9. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
    Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for metastatic bladder cancer; the EORTC experience.
    Stoter G
    Prog Clin Biol Res; 1988; 260():471-9. PubMed ID: 3283767
    [No Abstract]   [Full Text] [Related]  

  • 11. [Conservative treatment of infiltrating cancer of the bladder: neoadjuvant chemotherapy and radiotherapy].
    Prié L; Gaston R; Ferrière JM; Richaud P; Bui BN; Guillou ML
    Cancer Radiother; 1998 Apr; 2 Suppl 1():62s-66s. PubMed ID: 9749081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with cyclophosphamide, doxorubicin, and bleomycin for metastatic transitional cell carcinoma of the urinary tract.
    Levi JA; Aroney RS; Dalley DN
    Cancer Treat Rep; 1980; 64(8-9):1011-3. PubMed ID: 6160912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical and systemic chemotherapy of murine bladder cancer.
    Soloway MS
    Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
    [No Abstract]   [Full Text] [Related]  

  • 14. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
    Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
    Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MEC treatment (methotrexate, etoposide, cisplatin) for urothelial cancer].
    Miura T; Murai T; Shimura H; Kondo I
    Gan To Kagaku Ryoho; 1992 May; 19(5):731-3. PubMed ID: 1580650
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
    Schrier BP; Peters M; Barentsz JO; Witjes JA
    Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
    Walther PJ
    Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of combination chemotherapy of tegafur, adriamycin and cisplatin on patients with advanced relapsing prostatic carcinoma and advanced bladder tumor].
    Yoshida K; Nakame Y; Horiuchi S; Kaneoya F; Kuroda T; Tanoiri A; Koizumi M; Takahashi M; Negishi T; Saitoh H
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1083-5. PubMed ID: 3083786
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aggressive preoperative chemotherapy in infiltrating bladder carcinoma with a combination of cisplatin, cyclophosphamide and adriamycin. Preliminary report].
    Martínez-Piñeiro JA; de la Peña JJ; Hidalgo L; Cisneros J; Jiménez de León J; Machuca J
    Arch Esp Urol; 1986; 39(1):33-46. PubMed ID: 3707210
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.